Monday, November 25, 2024
HomeTagsPhase II Study

Phase II Study

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, announced the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics